Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Review of the Il-18 and IL37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets

Version 1 : Received: 17 June 2024 / Approved: 18 June 2024 / Online: 18 June 2024 (08:16:27 CEST)

How to cite: Rusiñol, L.; Puig, L. Review of the Il-18 and IL37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. Preprints 2024, 2024061196. https://doi.org/10.20944/preprints202406.1196.v1 Rusiñol, L.; Puig, L. Review of the Il-18 and IL37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets. Preprints 2024, 2024061196. https://doi.org/10.20944/preprints202406.1196.v1

Abstract

Atopic dermatitis and psoriasis are prevalent inflammatory skin conditions with diverse treatment options. Despite advances in understanding their underlying mechanisms, recent research highlights the significance of interleukins IL-18 and IL-37 as potential therapeutic targets. This review synthesizes knowledge on these interleukins, their roles in atopic dermatitis and psoriasis, and emerging treatment strategies. Findings of a literature search up to May 30, 2024 underscore a research gap in IL-37-targeted therapies. Conversely, IL-18-focused treatments have demonstrated promise in adult-onset Still’s Disease, warranting further exploration for their potential efficacy in psoriasis and atopic dermatitis.

Keywords

psoriasis; atopic dermatitis; IL-18; IL-37

Subject

Medicine and Pharmacology, Dermatology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.